Meet with Rob Singer of Rosa Market Modeling at the Biotechgate Digital Partnering Meeting from February 6-10, 2023. For more information about the event, see https://partnering.biotechgate.com/.
Rosa is seeking PhD students, postdoctoral scholars, and early researchers in academia & industry to present as part of the Rosa World Wide Webinar series. These webinars will support outstanding early career investigators by providing an opportunity for them to show their research to a broad audience. We are looking for presenters whose research advances the adoption of modeling and simulation in drug development.
If you are an early career investigator with an interesting research presentation, please send a title, abstract, and a short bio to email@example.com.
Rosa has been hosting the monthly “Impact” webinar series since 2011 and each Webinar draws several hundred attendees from a mix of drug development disciplines. The speakers and audience come from both industry and academia. Each Webinar includes a slide presentation followed by a brief discussion, lasting about an hour total. After the webinar, a recording of the webinar and slides from the webinar are posted on the webinar archive site. For your reference, you can see archived sessions and the upcoming Webinar schedule here: http://www.rosaandco.com/webinars.
Deadline to apply to present as an early career investigator is April 1, 2023.
Rosa will be participating in the Biotechgate Digital Partnering Meeting. Meet with Rob Singer of Rosa Market Modeling at the Digital Partnering Meeting from November 28 to December 2, 2022. For more information on the event, pleas see the websites at https://partnering.biotechgate.com/login/index/BDP1122 and https://www.digitalpartnering.com/.
Rosa & Co. announced today the publication of an article titled, “From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology (QSP) Modeling in Cancer Immunotherapy,” which was published online ahead of print in Clin Pharmacol Ther. 2022 Oct 25. To read the article: https://ascpt.onlinelibrary.wi...
Rosa & Co. announced today the publication of an article titled, “Quantitative Systems Pharmacology Model of the Amyloid Pathway in Alzheimer’s Disease: Insights into the Therapeutic Mechanisms of Clinical Candidates,” which was published online ahead of print on CPT Pharmacometrics Syst Pharmacol. on October 24, 2022. To read the article: https://ascpt.onlinelibrary.wi...
Rosa & Co. is pleased to announce the presentation of two posters at the 2022 ACoP13 meeting. The posters ‘QSP Model of Aß Accumulation Predicts Different Treatment Effects at Different Stages of Alzheimer’s Disease.’ and ‘Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model.’ will be presented on October 31 at the the ACoP13 meeting in Aurora Colorado. For more information about the meeting, see https://www.go-acop.org/.
Matt Marano, Chief Commercial Officer for Rosa & Co. will be attending the upcoming Cell and Gene Therapy Strategy Meeting: Europe 2022 on Tuesday, October 11, 2022. See the following link for more details. https://proventainternational.com/211-partner/
Meet with Rob Singer from Rosa & Co. at Biopharm America, Oct 4-5, 2022. https://buff.ly/3V0T5rd. Rob will be speaking with biotech and pharmaceutical companies about Rosa’s ForecastMD™ Platform and to investors about Rosa’s new DueDiligenceMD service. This will be a virtual meeting.
Rosa & Co. is pleased to announce it is offering DueDiligenceMD in addition to the ForecastMD™ Research Platform. For organizations that are evaluating assets for in-licensing, partnering, or acquisition, DueDiligenceMD quantifies and explains the expected physician demand for the asset, based on primary market research and an Excel®-based Revenue Model. DueDiligenceMD projects are typically completed within two weeks.
Rosa & Co. is also enhancing our PhysioPD® Research with the use of Artificial Intelligence/ Machine Learning (AI/ML) techniques. PhysioPD Research provides biological context, facilitates insight into dynamics and causality, and supports hypothesis generation. Adding AI/ML techniques to PhysioPD Research speeds the identification of networks from data, supports empirical model and Virtual Patient creation, and enriches the insights extracted from simulation results.
See the press release at https://www.einnews.com/pr_new...
Rosa & Co. LLC is pleased to announce that Dr. Bill Brastow, Chief Technology Officer for Rosa Market Modeling, will present a webinar "Injecting Reality into Commercial Due Diligence for In-Licensing, Partnering or Purchasing Pharmaceutical Assets in Development" on Wednesday, August 17, 2022, at 12:00 to 1:00 pm EDT.
As part of the Rosa World-Wide Webinar Series, this webinar focuses on how pharmaceutical and biotech companies can inject reality into the commercial opportunity analysis by measuring expected physician demand for the drug to inform revenue projections and decisions about in-licensing, partnering, or purchasing these assets.
To learn more or register for the webinar, see: https://rosaandco.com/webinars
Rosa will be at Oncology Europe 2022 on June 14, 2022. Mike Reed, Chief Scientist, PhysioPD will be presenting. Come meet us live and in person! https://buff.ly/3KgHmir
Rosa & Co is pleased to announce the release of a new video discussing how a ForecastMD™ Market Model can quantify physician demand for a prescription drug or diagnostic test under multiple product profiles or competitive scenarios. The video is part of Rosa’s 20th-anniversary celebration. The video is available at Market Model Implications.
Rosa & Co is pleased to announce the release of a new video discussing how the ForecastMD™ Excel-based Market Model is a durable asset that our clients can use over multiple years to quantify physicians' demand for their prescription drug or diagnostic test as the market changes over time.
The video is part of Rosa’s 20th anniversary celebration. The video is available at Durable Asset.
Come see Rosa at the Oncology Strategy Meeting, San Francisco, May 11, 2022. Live and in person! https://buff.ly/3LIhPyJ
Rosa and Servier will be presenting a talk and a poster on modeling systemic lupus erythematosus next week at Quantitative Systems Pharmacology Conference 2022 (QSPC2022), in Leiden, the Netherlands https://www.qspc.eu/qspc2022. Dr. Christina Friedrich from Rosa will be presenting “Predicted efficacy of a pan neutralizing anti interferon-alpha (IFN-α) monoclonal antibody in a virtual systemic lupus erythematosus (SLE) patient cohort using a mechanistic SLE PhysioPD QSP model” on Friday 4/22. Rosa & Co. is a proud sponsor for this important QSP conference.
Rosa & Co is pleased to announce the release of a new video discussing how our ForecastMD™ Market Model Platform can quantify how a new prescription drug or diagnostic test may take market share from current options.
The video is part of Rosa’s 20th-anniversary celebration. Click to see the ForecastMD™ Platform Dynamics video.
Rosa & Co is pleased to announce the release of a new video discussing how our ForecastMD™ Market Model Platform helps commercial teams from biotechnology, pharmaceutical, and diagnostic companies simulate physician demand for their new product in a variety of competitive scenarios.
The video is part of Rosa’s 20th-anniversary celebration. Click here to see the ForecastMD™ Platform Overview Video.
Rosa & Co is thrilled to announce the release of a video celebrating its 20th-anniversary. The company is celebrating this historic event with videos, events, and news throughout the year. Click here to see our 20th-Anniversary Video.
Rosa & Co is pleased to announce the release of a new white paper “Commercializing Life Science Products. Which Product Properties Are Important in Convincing Physicians and Patients to Use My Product? And How to Ask This Question”. The paper describes a scientific approach to HCP product selection.